Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

Annals of Surgical Oncology - United States
doi 10.1245/s10434-016-5600-x
Full Text
Abstract

Available in full text

Categories
OncologySurgery
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

ERβ Alters the Chemosensitivity of Luminal Breast Cancer Cells by Regulating P53 Function

Oncotarget
Oncology
2018English

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance With Standard Clinical Molecular Markers

BMC Medical Genomics
Genetics
2012English

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Role and Future Perspectives

ecancermedicalscience
Cancer ResearchOncology
2016English

Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer

Breast Care
SurgeryOncology
2017English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

Molecular Subtyping for Clinically Defined Breast Cancer Subgroups

Breast Cancer Research
Cancer ResearchOncology
2015English

PCA-PAM50 Improves Consistency Between Breast Cancer Intrinsic and Clinical Subtyping Reclassifying a Subset of Luminal a Tumors as Luminal B

Scientific Reports
Multidisciplinary
2019English

Neoadjuvant Chemotherapy in Breast Cancer

English

Basal Markers and Prognosis in Luminal Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy